JPM need-to-know, Part 2: GSK's cancer convictions; Amgen's diverse defense; GW's ambitions and more

8th January 2019 Uncategorised 0

The J.P. Morgan Healthcare Conference opened Tuesday with GlaxoSmithKline CEO Emma Walmsley’s rundown, featuring—of course—its $5 billion Tesaro buy. And you could say that Amgen CEO Bob Bradway’s presentation began late Monday, when the company rolled out another round of price cuts on its cholesterol drug Repatha. Stay tuned for Roche, Takeda, Sanofi and more.

More: JPM need-to-know, Part 2: GSK's cancer convictions; Amgen's diverse defense; GW's ambitions and more
Source: fierce